![Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder - Journal of the American Academy of Child & Adolescent Psychiatry Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder - Journal of the American Academy of Child & Adolescent Psychiatry](https://www.jaacap.org/cms/asset/c538884a-a227-4325-9eaf-5125addea69b/gr1.jpg)
Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder - Journal of the American Academy of Child & Adolescent Psychiatry
![JCM | Free Full-Text | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia JCM | Free Full-Text | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia](https://www.mdpi.com/jcm/jcm-11-03810/article_deploy/html/images/jcm-11-03810-g001.png)
JCM | Free Full-Text | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
![Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/c0a81b87-8ceb-4bbf-a493-55c6d4121bf6/gr1_lrg.jpg)
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity
![The All Randomized/Full Analysis Set (ICH E9)—May Patients be Excluded from the Analysis? | Semantic Scholar The All Randomized/Full Analysis Set (ICH E9)—May Patients be Excluded from the Analysis? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a000d1a89a3db891de4b3bb3228abdc3279a2e86/2-Table1-1.png)
The All Randomized/Full Analysis Set (ICH E9)—May Patients be Excluded from the Analysis? | Semantic Scholar
![Patient disposition. FAS, full analysis set; SAF, safety analysis set. | Download Scientific Diagram Patient disposition. FAS, full analysis set; SAF, safety analysis set. | Download Scientific Diagram](https://www.researchgate.net/publication/347877274/figure/fig2/AS:1024371401424896@1621240582003/Patient-disposition-FAS-full-analysis-set-SAF-safety-analysis-set.png)
Patient disposition. FAS, full analysis set; SAF, safety analysis set. | Download Scientific Diagram
![Subject disposition. Full analysis set (FAS) = all randomised subjects... | Download Scientific Diagram Subject disposition. Full analysis set (FAS) = all randomised subjects... | Download Scientific Diagram](https://www.researchgate.net/publication/262884185/figure/fig1/AS:272046726840330@1441872402241/Subject-disposition-Full-analysis-set-FAS-all-randomised-subjects-who-received-1.png)
Subject disposition. Full analysis set (FAS) = all randomised subjects... | Download Scientific Diagram
![Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b924feb9-e176-4656-86f6-570bbc62a9c4/cas13221-fig-0001-m.png)
Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library
![Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial | Nature Cancer Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial | Nature Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs43018-022-00503-w/MediaObjects/43018_2022_503_Fig1_HTML.png)